Investment Rating - The investment rating for the company is "Buy" (maintained) [3][15] Core Insights - The company's performance in Q2 shows steady growth, with a revenue of 774 million yuan in 2024, reflecting a year-on-year growth rate of 4.9% [5][3] - The net profit attributable to the parent company for 2024 is projected to be 190 million yuan, with a year-on-year growth of 26.9% [5][3] - The company is focusing on expanding its core components business for robotics, having completed the first production line for harmonic reducers [11][10] Financial Performance Summary - In 2024, the company reported a revenue of 774 million yuan, with a projected increase to 867 million yuan in 2025 and 977 million yuan in 2026 [3][5] - The net profit for 2024 is expected to be 190 million yuan, increasing to 218 million yuan in 2025 and 248 million yuan in 2026 [3][5] - The gross margin for 2024 is 32.5%, with a net margin of 24.5%, showing improvements in profitability [8][3] Growth Potential - The company has a strong presence in the automotive wheel hub bearing aftermarket, with a market share of less than 2% in a market worth approximately 53.88 billion yuan [7][3] - The company is actively expanding its global footprint, with 68.4% of its revenue coming from overseas markets in 2024 [9][10] - The establishment of a robotics components division is expected to create new growth opportunities, with significant investments planned for the harmonic reducer production line [11][10]

底部拐点可期，创新行情有望延续 ——医药生物 5 月月报暨年报/一季报总结 医药生物 证券研究报告/行业专题报告 2025 年 05 月 07 日 | | | 执业证书编号：S0740519040001 Email：zhujq@zts.com.cn | 基本状况 | | | --- | --- | | 上市公司数 | 498 | | 行业总市值(亿元) | 62,472.12 | | 行业流通市值(亿元) | 56,049.40 | 仓占比分析》2025-04-28 新成长》2025-04-20 3、《中国医药进出口分析；关注创 新、内需、国产替代机会》2025-04-12 | 评级： 增持（维持） | | | 重点公司基本状况 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 简称 | 股价 | | | EPS | | | | | PE | | | 评级 | | 分析师：祝嘉琦 | | | （元） | 2023A | ...

一般零售 | | | 执业证书编号：S0740524040004 Email：zhengch@zts.com.cn 执业证书编号：S0740523060001 Email：zhangji01@zts.com.cn 基本状况 | 总股本(百万股) | 638.34 | | --- | --- | | 流通股本(百万股) | 638.34 | | 市价(元) | 10.85 | | 市值(百万元) | 6,925.97 | | 流通市值(百万元) | 6,925.97 | 家家悦（603708.SH） 证券研究报告/公司深度报告 2025 年 05 月 08 日 | 评级： | 增持（首次） | 公司盈利预测及估值 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 指标 | | | | 2023A | 2024A | 2025E | 2026E | 2027E | | 分析师：郑澄怀 | | 营业收入（百万元） | | 17,763 | 18,256 | 18,566 | 19,258 | 20,066 | | 增长率 ...

医疗器械 | 基本状况 | | | --- | --- | | 总股本(百万股) | 416.52 | | 流通股本(百万股) | 212.93 | | 市价(元) | 79.01 | | 市值(百万元) | 32,908.94 | | 流通市值(百万元) | 16,823.80 | 地缘风险波动下业绩稳健，全球测序装机稳步攀升 华大智造（688114.SH） 证券研究报告/公司点评报告 2025 年 05 月 08 日 | 评级： | 增持（维持） | 公司盈利预测及估值 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 指标 | | 2023A | 2024A | 2025E | 2026E | 2027E | | 分析师：祝嘉琦 | | 营业收入（百万元） | | 2,911 | 3,013 | 3,607 | 4,500 | 5,597 | | | | 增长率 yoy% | | -31% | 3% | 20% | 25% | 24% | | 执业证书编号：S0740519040001 | | 归母净利 ...

北交所板块涨幅领先，多家拟上市企业更新审核状态 北交所 证券研究报告/行业定期报告 2025 年 05 月 08 日 报告摘要 北交所行情概览： 1）整体行情：截至 2025 年 4 月 30 日收盘，北证成份股 265 个，平均市值 27.8 亿 元。本周（2025.4.28-2025.4.30，下同）北证 50 指数涨跌幅 2.38%，收盘 1331.13 点；同期沪深 300、创业板指、科创 50 涨跌幅分别为-0.43%、0.04%、0.78%。 2）赛道行情：本周 A 股涨幅前五的行业为传媒、计算机、机械设备、电子、家用电 器，涨幅分别为 2.7%、2.5%、1.6%、1.3%、1.1%。 ——北交所周报（4.28-4.30） 3）个股行情：本周在北交所上市的 265 只个股中上涨 138 只、下跌 117 只、平盘 10 只，上涨比例 52.1%。 | 评级： 增持（维持） | | | --- | --- | | 分析师：冯胜 | | | 执业证书编号：S0740519050004 | | | Email：fengsheng@zts.com.cn | | | 北交所基本状况 | | | 上市公司数 ...

中 泰 证 券 研 究 所 专 业 ｜ 领 先 ｜ 深 度 ｜ 诚 信 ｜ 证 券 研 究 报 告 ｜ 1Q25保险资金重仓流通股深度跟踪 ——加仓交运、食饮，新进银行、通信 2 0 2 5 . 5 . 8 • 1Q25 主要鼓励政策为中央金融办《关于推动中长期资金入市工作的实施方案》、金监总局先后发布第二批长期 股票试点以及《关于调整保险资金权益类资产监管比例有关事项的通知 ◼ "中泰非银保险重仓流通股"体系介绍（欢迎关注Wind组合管理，PMS代码为W1428999213874） • 我们根据Wind平台收录的险资重仓流通股数据——即所有已披露定期报告的A股上市公司前十大流通股东名单 中含保险机构的持仓记录，经过调整后，形成分析样本集开展研究。2025年年初至今（2025年5月6日），组合 绝对回报为0.37%，相对回报为3.59%。 葛玉翔 证券分析师执业证书编号：S0740525040002 邮 箱：geyx01@zts.com.cn 蒋峤 证券分析师执业证书编号：S0740517090005 邮 箱：jiangqiao@zts.com.cn 1 摘要 ◼ 持续低利率环境下，险资再配置收益率面临考验， ...

证券研究报告/策略专题报告 2025 年 05 月 08 日 * [10] M. C. 执业证书编号：S0740519080003 Email：xuchi@zts.com.cn 分析师：张文宇 2025 年一季报业绩变化有何投资指引？ 三、价格压力整体持续，政策支持下部分行业"困境反转" 2023 年以来我国经济需求侧增速不足的问题逐渐凸显，造成上市公司"增量不增利"。 2025 年 Q1 共有 23 个行业销售净利率低于 10%，其中有 13 个行业低于 5%，地产板 块整体亏损。边际变化方面，25 年一季度有 19 个行业归母净利润增速高于营收增速。 上游周期方面，钢铁、有色、基础化工等行业出现"困境反转"，利润改善明显。中 游制造方面，一季度受益于需求增加以及"特朗普关税"预期带来的抢出口，机械设 备与汽车行业利润率持续上行。电力设备当前结构性产能过剩仍存在，营收有所提升 但利润下滑。下游消费方面，受益于消费券以旧换新等终端消费政策支持，家用电器 板块 25 年一季度归母净利润同比增长 25.12%，业绩大幅超预期。 四、PB-ROE 视角下，部分行业存在估值修复潜力 执业证书编号：S074052012 ...

| 评级： | 增持（维持） | 公司盈利预测及估值 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 指标 | | 2023A | 2024A | 2025E | 2026E | 2027E | | 分析师：祝嘉琦 | | 营业收入（百万元） | | 2,911 | 3,013 | 3,607 | 4,500 | 5,597 | | | | 增长率 yoy% | | -31% | 3% | 20% | 25% | 24% | | 执业证书编号：S0740519040001 | | 归母净利润（百万元） | | -607 | -601 | -177 | 7 | 182 | | Email：zhujq@zts.com.cn | | 增长率 yoy% | | -130% | 1% | 70% | 104% | 2,543% | | | | 每股收益（元） | | -1.46 | -1.44 | -0.43 | 0.02 | 0.44 | | 分析师：谢木青 | | 每股现金流量 | | -2.09 | -1.86 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative performance increase of over 15% against the benchmark index in the next 6 to 12 months [4][23]. Core Views - The company has shown a strong performance in Q1 2025, with revenue reaching 759 million yuan, a year-on-year increase of 10.13% and a quarter-on-quarter increase of 8.69%. The net profit attributable to the parent company was 86.18 million yuan, up 112.70% year-on-year and 395.35% quarter-on-quarter [6]. - The report highlights that the company is approaching a performance inflection point, driven by robust growth in new business segments and significant improvements in profitability [3][6]. - The company is positioned as a leader in the raw material drug market, particularly in the low-price range of sartans, while non-sartan raw materials are identified as a core growth driver for the future [6]. Summary by Sections Financial Performance - For 2023, the company reported a revenue of 2,527.27 million yuan, with a year-on-year decline of 5.23%. However, projections for 2024 and beyond show a recovery with revenues expected to grow to 2,630.81 million yuan in 2024 and reaching 4,279.35 million yuan by 2027 [4][22]. - The net profit attributable to the parent company is forecasted to increase significantly from 27.36 million yuan in 2023 to 461 million yuan in 2027, reflecting a compound annual growth rate of 29.71% [4][22]. Business Segments - The report details that the non-sartan raw material segment achieved revenue of 189 million yuan in Q1 2025, marking a 57% year-on-year increase, indicating strong growth potential [6]. - The formulation business generated 80.77 million yuan in revenue, a 97% increase, with the number of approved formulations rising to 63, suggesting ongoing contributions to revenue growth [6]. Profitability Metrics - The gross margin for Q1 2025 was reported at 37.39%, an increase of 2.06 percentage points year-on-year, while the net margin reached 11.35%, up 5.47 percentage points year-on-year [6]. - The report anticipates that the company's gross margin will continue to improve, reaching 41.0% by 2027 [22]. Research and Development - R&D expenses for Q1 2025 were 53.45 million yuan, accounting for 7.04% of revenue, indicating a stable investment in innovation [6][22]. - The company plans to complete the process validation for 12 new raw material drug varieties by 2024, which is expected to drive future growth [6].

黑色家电 执业证书编号：S0740522080001 Email：yaowei@zts.com.cn 执业证书编号：S0740524060003 Email：wujm@zts.com.cn | 基本状况 | | | --- | --- | | 总股本(百万股) | 1,304.97 | | 流通股本(百万股) | 1,295.09 | | 市价(元) | 23.61 | | 市值(百万元) 流通市值(百万元) | 30,810.39 30,577.18 | 2025-04-07 升》2024-11-03 3、《【中泰家电】海信视像 24H1：短 期收入利润均承压，长期逻辑不变》 2024-08-26 海信视像（600060.SH） 证券研究报告/公司点评报告 2025 年 05 月 08 日 | 评级： | 买入（维持） | 公司盈利预测及估值 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 指标 | | | | 2023A | 2024A | 2025E | 2026E | 2027E | | 营业收入（百万元） ...